Ursula Mason, BSc

Senior Partner

Email: ursula.mason@transcrip-partners.com

Ursula Mason is a specialist in Pharmaceutical Medicine with more than 25 years experience across drug discovery, development and commercialisation, in a number of blue chip pharmaceutical companies, including GlaxoSmithKline, Serono and Pharmacia. Ursula has worked in a broad variety of therapy areas, and has particular expertise in neurosciences and immuno-inflammation. In addition to developing small molecules, Ursula has extensive experience in leading global project teams for biopharmaceuticals: delivering the global registration programme for Serono/Celltech's growth hormone; co-leading two SB/IDEC anti-CD4 monoclonal antibody (mAb) clinical development programmes in rheumatoid arthritis; and, most recently, leading GSK/Genmab's anti-CD20 mAb multiple sclerosis development and assuming leadership of GSK's beta amyloid mAb project team for Alzheimer's disease.

In addition to her track record of successful project leadership and clinical research, Ursula has a broad business background, with experience of business development, business operations, Medical Affairs and business strategy. This included membership of GSK's Neurosciences Medicines Development Centre Leadership Team, as Global Business Operations Head, where she led the creation of the MDC's Business Plan. She has also successfully led a number of cross-R&D change management projects.

Ursula has a BSc in Physiology from the University of Leeds, and has undertaken additional business training.